WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

2025 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "**Company**", together with its subsidiaries, collectively "**We**" or "**Our**") for financial year 2025 (the "**2025 Third Quarterly Report**"). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards Accounting Standards issued by the International Accounting Standards Board (the "**IFRSs**") (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 24, 2025

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*

I. Important Notice

1.1 The Board and the Directors, the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2025 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2025 Third Quarterly Report, and shall assume several and joint legal responsibilities.

1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2025 Third Quarterly Report.

1.3 The 2025 Third Quarterly Report of the Company has not been audited.

1.4 Definitions

Definitions of frequently-used terms

"A Share(s)"	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
"API"	active pharmaceutical ingredient
"Board"	the board of Directors of the Company
"CDMO"	Contract Development and Manufacturing Organization, a CMO that in addition to comprehensive drug manufacturing services, also provide process development, formulation development, clinical trial medications, production of chemically or biologically synthesized active pharmaceutical ingredients, intermediate manufacturing, formulation production (such as powders and injectables), and packaging, as well as customized research and development services for related products
"China" or "PRC"	the People's Republic of China, which for the purpose of this quarterly report and for geographical reference only, refers to mainland China

"clinical trial(s)"	systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug
"CRDMO"	Contract Research Development and Manufacturing Organization
"CRO"	Contract Research Organization, an academic or commercial scientific institution that provides specialized services to pharmaceutical companies and research institutions during the drug development process through contractual agreements
"Director(s)"	the director(s) of the Company or any one of them
"end of the Reporting Period"	September 30, 2025
"FDA"	Food and Drug Administration in the U.S.
"H Share(s)"	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on The Stock Exchange of Hong Kong Limited
"IND"	investigational new drug
"NDA"	new drug application
"QoQ"	for the Reporting Period as compared to the previous quarter
"Reporting Period"	July 1, 2025 to September 30, 2025
"RMB" or "RMB million" or "billion"	Renminbi yuan or million yuan or billion yuan
"R&D"	research and development

"Share(s)"	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
"Small molecule drug"	small molecule drugs mainly refer to chemically synthesized drugs, typically with a molecular weight of less than 1,000 daltons, with advantages such as wide application and based on well-established theories, currently, the majority of mature drugs on the market are small molecule drug
"SMO"	Site Management Organization
"WuXi Biology"	biology business of the Company
"WuXi Chemistry"	chemistry business of the Company
"WuXi Testing"	testing business of the Company
"year-over-year" or "YoY"	for the first three quarters of 2025 as compared to the same period in the previous year
"%"	percentage

II. Company Profile

As a trusted partner and significant contributor to global pharmaceutical and life sciences industry, the Company is committed to advancing medical innovation worldwide through providing a broad portfolio of R&D and manufacturing services. With operations across Asia, Europe, and North America, our unique business models of "CRDMO", help customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

The Company has always adhered to the highest international quality control standards. Since its establishment, the Company has earned a well-recognized reputation for excellent service records and a comprehensive intellectual property protection system in the global pharmaceutical research and development industry. The service quality developed by the Company is highly recognized and trusted within the industry. The Company continuously optimizes and explores business synergies across sectors to better serve global clients, further strengthens its unique integrated CRDMO business model, and provides one-stop services to meet clients' needs from discovery to development and manufacturing.

III. Major financial data

1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period	Year-over-year increase/decrease (%)	From the beginning of the year to the end of the Reporting Period	Year-over-year increase/decrease (%)
Revenue	12,057,434,626.40	15.26	32,856,716,508.86	18.61
Total profit	5,129,651,792.47	82.89	15,037,068,350.44	91.45
Net profit attributable to the owners of the Company	3,514,630,329.36	53.27	12,075,512,956.92	84.84
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	3,940,286,547.04	73.75	9,522,413,145.23	42.51
Net cash flow from operating activities	N/A	N/A	11,412,834,667.47	36.21
Basic earnings per share (RMB/share)	1.24	55.00	4.25	88.89
Diluted earnings per share (RMB/share)	1.22	54.43	4.21	87.95
Weighted average return on net assets (%)	5.34	Increased by 1.22 percentage points	19.26	Increased by 7.53 percentage points

	As at the end of the Reporting Period	As at the end of the previous year	Increase/ decrease as at the end of the Reporting Period as compared to the end of the previous year (%)
Total assets	94,606,135,416.07	80,325,824,408.75	17.78
Equity attributable to the owners of the Company	70,948,120,408.17	58,632,715,174.37	21.00

2. Non-recurring gain or loss items and amounts

✓ Applicable ☐ Not applicable

Unit: RMB

Non-recurring gain or loss	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets, including the write-off portion of asset impairment provisions that have been made	-72,171,669.37	3,223,327,233.47	It was mainly due to the gains generated from the sale of part of the shares of an associate WuXi XDC Cayman Inc. held by the Company.
Government grants included in profit or loss of the current period, except for those that are closely related to the Company's normal business operations, in compliance with policy regulations, and have a continuous impact on the Company's profit or loss according to established standards	15,754,971.29	134,761,993.84	
Gain or loss arising from changes in fair value of financial assets and financial liabilities held by a non-financial enterprise, and gain or loss arising from disposal of financial assets and financial liabilities, except effective hedging business related to the Company's normal operations	319,766,438.47	101,319,713.72	It was mainly due to changes in fair value and gains and losses on disposal of non-current financial assets and derivative financial instruments.
One-off costs incurred by the enterprise as a result of the discontinuation of the relevant business activities, e.g. staff settlement expenses, etc.	-4,804,890.31	-146,626,124.72	It was due to losses and expenses related to the discontinued operations of the Company.
Other non-operating income and expenses other than the above items	-4,782,447.15	-25,998,395.86	
Less: Effect of income tax	686,301,871.14	704,670,862.37	
Impact on non-controlling interests (after tax)	-6,883,250.53	29,013,746.39	
Total	-425,656,217.68	2,553,099,811.69	

Reasons should be provided for identifying items not listed in the "Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss" as non-recurring gain or loss items with significant amounts, as well as for classifying the non-recurring gain or loss items listed in the "Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1— Non-recurring Gain or Loss" as recurring gain or loss items.

☐ Applicable ✓ Not applicable

3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

✓ Applicable ☐ Not applicable

Item	Change for the Reporting Period (%)	Change for the period from the beginning of the year to the end of the Reporting Period (%)	Main Reasons
Revenue	15.26	18.61	Please refer to the analysis below for details.
Total profit	82.89	91.45	It was mainly due to the Company maintaining a laser focus on and strengthening the Company's CRDMO business model, with continued revenue growth, ongoing optimization of production processes and operational efficiency, and enhanced capacity efficiency resulting from growth in late-stage clinical and commercialization projects, all of which contributed to the increase in net profit. Meanwhile, the gains generated from the sale of part of the shares of an associate WuXi XDC Cayman Inc. held by the Company further contributed to the increase in profit.
Net profit attributable to the owners of the Company	53.27	84.84	
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	73.75	42.51	With continuous steady growth in revenue, the Company has further demonstrated its economies of scale through continuously optimizing operational efficiency and increasing capacity utilization.
Basic earnings per share (RMB/share)	55.00	88.89	It was mainly attributable to the Company's robust profit growth.
Diluted earnings per share (RMB/share)	54.43	87.95	
Net cash flow from operating activities	N/A	36.21	It was primarily due to the strong profit growth, coupled with healthy working capital turnover management and continuously improving financial management capabilities, further strengthening financial stability.

Unit: Ten thousand RMB

Reportable segments	First three quarters of 2025	First three quarters of 2024	Change (%)
WuXi Chemistry	2,597,805.52	2,009,380.97	29.28
WuXi Testing	416,947.38	417,113.77	-0.04
WuXi Biology	194,727.30	182,594.01	6.64
Others	35,526.27	39,680.65	-10.47
Subtotal of Continuing Operations	3,245,006.48	2,648,769.39	22.51
Discontinued Operations *(Note 1)*	40,665.18	121,430.83	-66.51
Total	3,285,671.65	2,770,200.23	18.61

Note 1: According to the PRC Accounting Standards for Business Enterprises, the discontinued operations include the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year. Comparative disclosures have been adjusted accordingly.

Note 2: Any discrepancies between the total shown and the sum of the mounts listed in the above table and the following paragraphs are due to rounding.

By the end of September 2025, backlog for continuing operations reached RMB59.88 billion, up 41.2% YoY. In the first three quarters of 2025, revenue from continuing operations was RMB32.45 billion: revenue from US-based customers increased 31.9% YoY to RMB22.15 billion; revenue from Europe-based customers increased 13.5% YoY to RMB3.84 billion; revenue from China-based customers increased 0.5% YoY to RMB5.04 billion; and revenue from other regions increased 9.2% YoY to RMB1.42 billion. The above revenue by region is presented based on the country/region of domicile of customers' parent company.

In the first three quarters of 2025, total revenue reached RMB32.86 billion, up 18.6% YoY. Revenue from continuing operations was up 22.5% YoY, among which:

(1) Revenue from WuXi Chemistry reached RMB25.98 billion, up 29.3% YoY.

— Small molecule drug discovery service ("**R**") continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 430,000 new compounds to customers. In the meantime, 250 molecules were converted from R to D phase in the first three quarters of 2025. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business.

— Small molecule development and manufacturing ("**D**" & "**M**", Development and Manufacturing) services remains strong. The small molecule CDMO pipeline continued to expand. Revenue of small molecule D&M services rose 14.1% YoY to RMB14.24 billion. In the first three quarters of 2025, 621 new molecules were added to the small molecule D&M pipeline. As of September 30, 2025, our small molecule D&M pipeline reached 3,430 molecules, including 80 commercial projects, 87 in phase III, 374 in phase II and 2,889 in phase I and pre-clinical stages. This represents an increase of 15 projects in the commercial and phase III stages during the first three quarters of 2025. We continued to build small molecule capacity. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. The total reactor volume of small molecule APIs is expected to reach over 4,000kL by the end of 2025.

— TIDES business (oligo and peptides) sustains rapid growth. With the ramp-up of new capacities released sequentially each quarter last year, in the first three quarters of 2025 TIDES revenue grew 121.1% YoY to RMB7.84 billion. As of September 30, 2025, TIDES backlog grew 17.1% YoY. TIDES D&M customers grew 12% YoY, while the number of TIDES molecules grew 34% YoY. In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule, the Company's total reactor volume of Solid Phase Peptide Synthesizers has been increased to more than 100,000L.

(2) Revenue from WuXi Testing reached RMB4.17 billion.

— Revenue of lab testing services grew 2.7% YoY to RMB2.96 billion. Of which, drug safety evaluation services revenue resumed positive YoY growth, while maintaining an industry-leading position in the Asia-Pacific region. The Company is committed to actively enabling customers' global licensing. New modality business continued to develop, while the Company maintained its leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides. The Company continued to advance automation. DMPK successfully launched its proprietary all-in-one compound identification software, enhancing efficiency in spectral interpretation and metabolite identification for nucleic acids and peptides by 83%. The Suzhou facility has successfully passed 4 consecutive FDA on-site inspections.

— Revenue for clinical CRO & SMO was down 6.4% YoY to RMB1.21 billion due to market pricing impact. Of which, SMO revenue was down 0.7% YoY as backlog gradually converted into revenue, while maintaining its industry leading position in China. During the first three quarters of 2025, our clinical CRO business supported customers in obtaining 19 IND approvals and submitting for 2 NDA filings. The SMO business supported 75 new drug approvals for customers. The SMO business has supported 331 new drug approvals in total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer and cardiovascular disease, etc.).

(3) Revenue from WuXi Biology reached RMB1.95 billion, up 6.6% YoY.

— WuXi Biology follows the science, continuously strengthens drug discovery capabilities in emerging areas and actively grows overseas businesses. It efficiently generates downstream opportunities for CRDMO model by continuously contributing more than 20% of the Company's new customers.

— We accelerated advancements in *in vitro* integrated screening technologies and continued to improve *in vivo* pharmacology capabilities, resulting in rapid YoY and QoQ revenue growth. With its competitive edge continuously strengthened, the non-oncology business has achieved strong revenue growth, becoming an important contributor to business growth.

— New modality drug discovery services continue to perform well, contributing more than 30% of WuXi Biology's total revenue.

The Company expects continuing operations revenue to resume double-digit growth in 2025, with its YoY growth rate raised to 17–18%, up from the prior 13–17%. As a result, the Company expects full-year total revenue of RMB43.5–44.0 billion, up from the prior RMB42.5–43.5 billion. The Company focuses on the core CRDMO business and continuously improved production and operating efficiency.

The abovementioned operating performance forecast for the full year of 2025 is made based on the current order backlog of the Company. In addition, such operating performance forecast is subject to various prerequisites, including the stable development of the global pharmaceutical industry, the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Further, such operating performance forecast does not constitute a profit forecast by the management of the Company for the full year of 2025 nor a substantive undertaking by the Company to investors. Its realization is subject to various factors including but not limited to changes in internal and external environment, where greater uncertainty exists.

IV. Information about shareholders

1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: Share

Total number of ordinary shareholders as at the end of the Reporting Period *(Note 1)*	274,117
Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	0

Shareholdings of top 10 Shareholders
(excluding shares borrowed from financial institution backed securities)

Full name of shareholders	Nature of shareholders	Number of Shares held	Percentage (%)	Number of Shares subject to trading restrictions	Pledged, marked or frozen Shares	
					Status	Number
HKSCC NOMINEES LIMITED *(Note 2)*	Overseas legal entity	478,124,762	16.1219	0	Unknown	0
Hong Kong Securities Clearing Company Limited *(Note 3)*	Overseas legal entity	248,930,541	8.3937	0	Nil	0
G&C VI Limited	Overseas legal entity	143,015,795	4.8223	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	104,626,051	3.5279	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))	Other	87,074,568	2.9361	0	Nil	0
G&C V Limited	Overseas legal entity	73,105,843	2.4651	0	Nil	0
Industrial and Commercial Bank of China — SSE 50 Exchange-traded Open-end Index Securities Investment Funds (中國工商銀行 — 上證50交易型開放式指數證券投資基金)	Other	47,780,714	1.6111	0	Nil	0
Industrial and Commercial Bank of China Limited — Huatai-PB CSI 300 ETF (中國工商銀行股份有限公司 — 華泰柏瑞滬深300交易型開放式指數證券投資基金)	Other	42,681,527	1.4392	0	Nil	0
G&C VII Limited	Overseas legal entity	37,853,259	1.2764	0	Nil	0
Shanghai Houshen Investment Center (Limited Partnership) (上海厚燊投資中心 (有限合夥))	Other	34,881,982	1.1762	0	Nil	0

Shareholdings of top 10 holders of Shares not subject to trading restrictions (excluding shares borrowed from financial institution backed securities)

Full name of shareholders	Number of Shares not subject to trading restrictions	Class and number of Shares: Class	Number
HKSCC NOMINEES LIMITED (Note 2)	478,124,762	Overseas-listed foreign shares	478,124,762
Hong Kong Securities Clearing Company Limited (Note 3)	248,930,541	RMB-denominated ordinary shares	248,930,541
G&C VI Limited	143,015,795	RMB-denominated ordinary shares	143,015,795
G&C IV Hong Kong Limited	104,626,051	RMB-denominated ordinary shares	104,626,051
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))	87,074,568	RMB-denominated ordinary shares	87,074,568
G&C V Limited	73,105,843	RMB-denominated ordinary shares	73,105,843
Industrial and Commercial Bank of China — SSE 50 Exchange-traded Open-end Index Securities Investment Funds (中國工商銀行 — 上證50交易型開放式指數證券投資基金)	47,780,714	RMB-denominated ordinary shares	47,780,714
Industrial and Commercial Bank of China Limited — Huatai-PB CSI 300 ETF (中國工商銀行股份有限公司 — 華泰柏瑞滬深300交易型開放式指數證券投資基金)	42,681,527	RMB-denominated ordinary shares	42,681,527
G&C VII Limited	37,853,259	RMB-denominated ordinary shares	37,853,259
Shanghai Houshen Investment Center (Limited Partnership)(上海厚燊投資中心(有限合夥))	34,881,982	RMB-denominated ordinary shares	34,881,982
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, G&C VII Limited, Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) and Shanghai Houshen Investment Center (Limited Partnership) being part of the top 10 shareholders of the Company, are acting in concert.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

Note 1: As of the end of the Reporting Period, the total number of ordinary shareholders was 274,117, among them, there were 274,055 holders of A Shares and 62 registered holders of H Shares.

Note 2: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Note 3: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

Note 4: In the event of any discrepancy between the English translation and the Chinese version of the full name of shareholder, the Chinese version shall prevail.

2. Participation of shareholders holding 5% or more of the shares, top 10 shareholders and top 10 holders of shares not subject to trading restrictions in the borrowing of shares from financial institution backed securities

□ Applicable ✓ Not applicable

3. Changes of top 10 shareholders and top 10 holders of shares not subject to trading restrictions as compared with the previous period arising from borrowing/return of shares from financial institution backed securities

□ Applicable ✓ Not applicable

V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to

□ Applicable ✓ Not applicable

VI. Quarterly financial statements

1. Type of auditor's opinion

□ Applicable ✓ Not applicable

2. Financial statements

Consolidated Balance Sheet

As at September 30, 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	As at September 30, 2025	As at December 31, 2024
Current Assets:		
Bank balances and cash	29,438,763,964.44	18,322,034,067.70
Financial assets held for trading	3,560,951,646.05	1,233,983,963.56
Derivative financial assets	1,825,522.26	—
Note receivables	24,070,487.20	92,672,778.12
Trade receivables	8,440,088,868.81	7,951,700,878.82
Prepayments	249,903,440.34	225,725,044.84
Other receivables	493,409,032.07	123,871,411.09
Including: Interest receivables	145,798,546.89	15,439,815.32
Dividend receivables	—	—
Inventories	7,843,744,998.67	5,399,747,062.06
Contract assets	819,019,237.79	988,835,929.58
Held for sale assets	515,727,429.43	2,191,331,709.82
Non-current assets due within one year	742,342,496.85	734,077,736.67
Other current assets	1,682,457,981.21	1,426,171,681.73
Total Current Assets	53,812,305,105.12	38,690,152,263.99
Non-current Assets:		
Long-term equity investments	1,943,078,812.64	2,325,547,530.62
Other non-current financial assets	8,350,830,303.38	8,943,404,353.91
Fixed assets	19,411,072,560.47	18,784,189,923.36
Construction in progress	5,848,288,554.04	5,965,794,321.58
Productive biological assets	1,085,705,000.00	1,062,969,000.00
Right-of-use assets	860,206,952.34	901,030,886.55
Intangible assets	1,396,909,976.18	1,574,802,246.74
Goodwill	865,960,177.60	972,352,431.55
Long-term deferred expenditures	412,493,218.41	526,785,195.82
Deferred tax assets	512,939,841.30	473,067,120.36
Other non-current assets	106,344,914.59	105,729,134.27
Total Non-current Assets	40,793,830,310.95	41,635,672,144.76
Total Assets	94,606,135,416.07	80,325,824,408.75

Item	As at September 30, 2025	As at December 31, 2024
Current Liabilities:		
Short-term borrowings	5,281,547,061.10	1,242,689,653.78
Derivative financial liabilities	2,855,672.55	202,036,417.92
Note payables	—	14,380,800.00
Trade payables	2,272,672,131.75	1,750,060,617.43
Contract liabilities	2,565,673,751.55	2,251,025,010.47
Payroll payables	2,214,297,963.72	2,147,243,194.57
Tax payables	2,521,862,090.80	1,210,636,121.99
Other payables	2,995,437,115.25	2,789,321,889.76
Including: Interest payables	908,179.17	26,619,858.52
Dividend payables	23,606,550.00	—
Held for sale liabilities	108,984,208.05	865,540,560.37
Non-current liabilities due within one year	180,466,661.01	260,096,805.26
Other current liabilities	1,294,458,646.69	3,493,083,819.15
Total Current Liabilities	19,438,255,302.47	16,226,114,890.70
Non-current Liabilities:		
Long-term borrowings	1,799,100,000.00	2,959,508,734.83
Lease liabilities	532,674,859.00	546,560,928.62
Deferred income	929,903,996.84	985,611,937.63
Deferred tax liabilities	433,703,953.06	522,414,281.40
Total Non-current Liabilities	3,695,382,808.90	5,014,095,882.48
Total Liabilities	23,133,638,111.37	21,240,210,773.18
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,965,692,554.00	2,887,992,582.00
Capital reserve	31,736,772,250.87	24,337,764,002.70
Less: Treasury shares	4,535,883,010.49	2,259,008,874.29
Other comprehensive income	216,081,914.03	300,888,716.77
Special reserve	—	—
Surplus reserve	1,436,108,602.50	1,357,438,183.52
Undistributed profit	39,129,348,097.26	32,007,640,563.67
Total Equity (or Shareholders' Equity) attributable to owners of the Company	70,948,120,408.17	58,632,715,174.37
Non-controlling interests	524,376,896.53	452,898,461.20
Total Owners' Equity (or Shareholders' Equity)	71,472,497,304.70	59,085,613,635.57
Total Liabilities and Owners' Equity (or Shareholders' Equity)	94,606,135,416.07	80,325,824,408.75

Person in charge of the Company: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

Consolidated Income Statement

January to September 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB   Type of audit: Unaudited

Item		First three quarters of 2025 (January–September)	First three quarters of 2024 (January–September)
I.	Total revenue	32,856,716,508.86	27,702,002,254.76
	Including: Revenue	32,856,716,508.86	27,702,002,254.76
II.	Total cost	21,256,267,707.67	19,967,164,047.62
	Including: Cost	17,538,098,637.79	16,440,256,129.17
	Taxes and surcharges	273,965,204.62	218,784,249.97
	Selling expenses	569,374,574.48	546,582,318.74
	Administrative expenses	1,858,526,669.26	1,869,468,114.84
	R&D expenses	825,650,523.10	954,042,826.94
	Finance expenses	190,652,098.42	-61,969,592.04
	Including: Interest expenses	226,711,873.66	150,222,876.33
	Interest income	678,141,337.63	467,311,764.91
	Add: Other income	228,351,689.81	287,254,161.42
	Investment gains (“-” indicating loss)	4,098,539,874.75	-164,809,637.05
	Including: Gains from investments in associates and joint ventures	440,685,763.54	198,950,236.95
	Gains from changes in fair value (“-” indicating loss)	-34,435,917.65	217,646,546.11
	Credit impairment losses (“-” indicating loss)	-346,855,872.70	-155,999,892.45
	Assets impairment losses (“-” indicating loss)	-410,113,443.18	-20,104,426.49
	Gains on assets disposal (“-” indicating loss)	-69,873,339.23	-7,955,695.32
III.	Operating profit (“-” indicating loss)	15,066,061,792.99	7,890,869,263.36
	Add: Non-operating income	12,551,180.53	5,586,936.32
	Less: Non-operating expenses	41,544,623.08	42,160,110.47
IV.	Total profit (“-” indicating total loss)	15,037,068,350.44	7,854,296,089.21
	Less: Income tax expenses	2,830,874,889.18	1,252,684,573.24

Item	First three quarters of 2025 (January–September)	First three quarters of 2024 (January–September)
V. Net profit ("-" indicating net loss)	12,206,193,461.26	6,601,611,515.97
(I) Classified by continuity of operations		
1. Net profit from continuing operations ("-" indicating net loss)	12,339,724,609.74	7,297,212,320.50
2. Net profit from discontinued operations ("-" indicating net loss)	-133,531,148.48	-695,600,804.53
(II) Classified by ownership		
1. Net profit attributable to the owners of the Company ("-" indicating net loss)	12,075,512,956.92	6,532,934,698.28
2. Net profit attributable to non-controlling shareholders ("-" indicating net loss)	130,680,504.34	68,676,817.69
VI. Other comprehensive income, net of tax	-95,953,157.33	-3,353,834.76
(I) Other comprehensive income attributable to owners of the Company, net of tax	-84,806,802.74	-3,156,713.02
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-84,806,802.74	-3,156,713.02
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	151,975,975.50	157,680,974.11
(6) Exchange difference on translation of foreign financial statements	-236,782,778.24	-160,837,687.13
(7) Others	—	—

Item	First three quarters of 2025 (January–September)	First three quarters of 2024 (January–September)
(II) Other comprehensive income attributable to non-controlling shareholders, net of tax	-11,146,354.59	-197,121.74
VII. Total comprehensive income	12,110,240,303.93	6,598,257,681.21
(I) Total comprehensive income attributable to owners of the Company	11,990,706,154.18	6,529,777,985.26
(II) Total comprehensive income attributable to non-controlling shareholders	119,534,149.75	68,479,695.95
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	4.25	2.25
(II) Diluted earnings per share (RMB per share)	4.21	2.24

For the business combination involving enterprises under common control during the Reporting Period, realized net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Person in charge of the Company: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

Consolidated Statement of Cash Flows

January to September 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item		First three quarters of 2025 (January–September)	First three quarters of 2024 (January–September)
I.	**Cash flow from operating activities:**		
	Cash received from sale of goods or rendering of services	34,327,532,724.92	29,359,129,012.71
	Refunds of taxes and surcharges	1,093,800,903.48	1,312,328,095.05
	Cash received relating to other operating activities	690,144,986.47	575,390,065.07
	Sub-total of cash inflow from operating activities	36,111,478,614.87	31,246,847,172.83
	Cash paid for purchasing goods and receiving services	13,228,850,010.16	10,928,215,498.32
	Cash paid to and on behalf of employees	7,928,078,759.92	8,183,330,993.39
	Payments of taxes and surcharges	2,160,136,328.87	2,369,175,464.68
	Cash paid relating to other operating activities	1,381,578,848.45	1,387,032,831.29
	Sub-total of cash outflow from operating activities	24,698,643,947.40	22,867,754,787.68
	Net cash flow from operating activities	11,412,834,667.47	8,379,092,385.15
II.	**Cash flow from investing activities:**		
	Cash received from disposal of investments	11,163,983,140.14	5,266,733,483.82
	Cash received from return on investments	237,240,096.62	242,713,508.52
	Net cash received from disposal of fixed assets, intangible assets and other long-term assets	9,761,249.99	9,734,408.38
	Net cash received from disposal of subsidiaries and other business entities	1,343,881,409.16	—
	Cash received relating to other investing activities	—	—
	Sub-total of cash inflow from investing activities	12,754,865,895.91	5,519,181,400.72
	Cash paid to acquire fixed assets, intangible assets and other long-term assets	3,566,317,746.46	2,491,653,740.12
	Cash paid to acquire investments	8,783,584,477.76	6,221,744,533.73
	Net cash paid to acquire subsidiaries and other business entities	—	—
	Cash paid relating to other investing activities	—	—
	Sub-total of cash outflow from investing activities	12,349,902,224.22	8,713,398,273.85
	Net cash flow from investing activities	404,963,671.69	-3,194,216,873.13

Item		First three quarters of 2025 (January–September)	First three quarters of 2024 (January–September)
III.	**Cash flow from financing activities:**		
	Cash received from capital contributions	6,995,823,546.01	16,427,943.88
	Including: Cash received from capital contribution by non-controlling shareholders of subsidiaries	—	—
	Cash received from borrowings	11,575,750,138.88	8,265,727,336.78
	Cash received relating to other financing activities	—	—
	Sub-total of cash inflow from financing activities	18,571,573,684.89	8,282,155,280.66
	Cash repayments of borrowings	8,718,797,498.61	6,957,913,214.43
	Cash payments for distribution of dividends, profits or interest expenses	4,966,801,138.59	3,049,740,937.38
	Including: Dividends and profits paid by subsidiaries to non-controlling shareholders	23,518,290.00	—
	Cash paid relating to other financing activities	4,463,317,745.01	4,179,385,606.75
	Sub-total of cash outflow from financing activities	18,148,916,382.21	14,187,039,758.56
	Net cash flow from financing activities	422,657,302.68	-5,904,884,477.90
IV.	**Effect of fluctuations in exchange rates on cash and cash equivalents**	-209,209,966.10	-9,427,113.53
V.	**Net increase in cash and cash equivalents**	12,031,245,675.74	-729,436,079.41
	Add: Balance of cash and cash equivalents at the beginning of the period	13,444,711,217.64	10,001,038,812.02
VI.	**Balance of cash and cash equivalents at the end of the period**	25,475,956,893.38	9,271,602,732.61

Person in charge of the Company: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

3. Adjustments on the financial statements at the beginning of the first year of adopting new accounting standards or standard interpretations since 2025

☐ Applicable ✓ Not applicable

4. Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

July to September 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	Continuing Operations		Discontinued Operations		Total	
	Third quarter of 2025 (July to September)	Third quarter of 2024 (July to September) (Restated)	Third quarter of 2025 (July to September)	Third quarter of 2024 (July to September) (Restated)	Third quarter of 2025 (July to September)	Third quarter of 2024 (July to September)
Revenue	12,044,962	10,063,435	12,473	397,649	12,057,435	10,461,084
Cost of sales	(6,052,235)	(5,586,727)	1,419	(477,086)	(6,050,816)	(6,063,813)
Gross profit (loss)	**5,992,727**	**4,476,708**	**13,892**	**(79,437)**	**6,006,619**	**4,397,271**
Other income	280,421	247,347	2	278	280,423	247,625
Other gains and losses	201,053	(595,854)	(13,026)	(6,669)	188,027	(602,523)
Impairment losses under expected credit losses ("**ECL**") model, net of reversal	(169,001)	(74,234)	—	1,722	(169,001)	(72,512)
Impairment losses of non-financial assets	(79,964)	—	—	—	(79,964)	—
Selling and marketing expenses	(175,460)	(166,424)	452	(22,636)	(175,008)	(189,060)
Administrative expenses	(717,999)	(587,502)	(3,808)	(99,886)	(721,807)	(687,388)
R&D expenses	(311,732)	(302,434)	508	(15,300)	(311,224)	(317,734)
Operating profit (loss)	**5,020,045**	**2,997,607**	**(1,980)**	**(221,928)**	**5,018,065**	**2,775,679**
Share of results of associates	199,850	87,117	—	—	199,850	87,117
Share of results of joint ventures	568	184	—	—	568	184
Finance costs	(88,819)	(48,498)	(11)	(9,739)	(88,830)	(58,237)
Profit (loss) before tax	**5,131,644**	**3,036,410**	**(1,991)**	**(231,667)**	**5,129,653**	**2,804,743**
Income tax expense	(1,583,807)	(487,380)	—	3,403	(1,583,807)	(483,977)
Profit (loss) for the period	**3,547,837**	**2,549,030**	**(1,991)**	**(228,264)**	**3,545,846**	**2,320,766**

	Third quarter of 2025 (July to September)	Third quarter of 2024 (July to September)
Other comprehensive (expense) income for the period		
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of financial statements of foreign operations	(54,245)	(429,330)
Fair value (loss) gain on hedging instrument designated in cash flow hedges	(3,823)	411,242
Other comprehensive expense for the period, net of income tax	**(58,068)**	**(18,088)**
Total comprehensive income for the period	**3,487,778**	**2,302,678**
Profit (loss) for the period attributable to owners of the Company:		
From continuing operations	3,516,621	2,521,377
From discontinued operations	(1,991)	(228,264)
	3,514,630	**2,293,113**
Profit for the period attributable to non-controlling interests:		
From continuing operations	31,216	27,653
	3,545,846	**2,320,766**
Total comprehensive income for the period attributable to:		
Owners of the Company	3,461,927	2,272,852
Non-controlling interests	25,851	29,826
	3,487,778	**2,302,678**
Earnings per share (expressed in RMB per share)		
From continuing and discontinued operations		
— Basic	1.24	0.80
— Diluted	1.22	0.79
From continuing operations		
— Basic	1.24	0.87
— Diluted	1.23	0.87

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

January to September 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	Continuing Operations		Discontinued Operations		Total	
	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September) (Restated)	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September) (Restated)	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September)
Revenue	32,450,065	26,487,694	406,652	1,214,308	32,856,717	27,702,002
Cost of sales	(17,394,564)	(15,171,308)	(343,301)	(1,432,533)	(17,737,865)	(16,603,841)
Gross profit (loss)	**15,055,501**	**11,316,386**	**63,351**	**(218,225)**	**15,118,852**	**11,098,161**
Other income	918,943	757,141	1,022	1,501	919,965	758,642
Other gains and losses	2,548,524	(387,416)	88,445	(6,723)	2,636,969	(394,139)
Impairment losses under expected credit losses ("**ECL**") model, net of reversal	(462,388)	(152,693)	2,801	(1,946)	(459,587)	(154,639)
Impairment losses of non-financial assets	(149,358)	—	(4,114)	—	(153,472)	—
Impairment losses of assets classified as held for sale	—	—	(120,737)	—	(120,737)	—
Selling and marketing expenses	(550,155)	(453,865)	(19,220)	(92,717)	(569,375)	(546,582)
Administrative expenses	(1,872,548)	(1,667,633)	(96,990)	(297,240)	(1,969,538)	(1,964,873)
R&D expenses	(817,274)	(907,460)	(8,377)	(46,583)	(825,651)	(954,043)
Operating profit (loss)	**14,671,245**	**8,504,460**	**(93,819)**	**(661,933)**	**14,577,426**	**7,842,527**
Share of results of associates	440,051	202,935	—	—	440,051	202,935
Share of results of joint ventures	635	(3,985)	—	—	635	(3,985)
Finance costs	(252,894)	(161,097)	(4,747)	(26,083)	(257,641)	(187,180)
Profit (loss) before tax	**14,859,037**	**8,542,313**	**(98,566)**	**(688,016)**	**14,760,471**	**7,854,297**
Income tax expense	(2,795,910)	(1,245,100)	(34,965)	(7,585)	(2,830,875)	(1,252,685)
Profit (loss) for the period	**12,063,127**	**7,297,213**	**(133,531)**	**(695,601)**	**11,929,596**	**6,601,612**

	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September)
Other comprehensive (expense) income for the period		
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of financial statements of foreign operations	(248,982)	(161,808)
Fair value gain on hedging instrument designated in cash flow hedges	153,028	158,454
Other comprehensive expense for the period, net of income tax	**(95,954)**	**(3,354)**
Total comprehensive income for the period	**11,833,642**	**6,598,258**
Profit (loss) for the period attributable to owners of the Company:		
From continuing operations	11,935,480	7,228,536
From discontinued operations	(133,531)	(695,601)
	11,801,949	**6,532,935**
Profit for the period attributable to non-controlling interests:		
From continuing operations	127,647	68,677
	11,929,596	**6,601,612**
Total comprehensive income for the period attributable to:		
Owners of the Company	11,717,142	6,529,778
Non-controlling interests	116,500	68,480
	11,833,642	**6,598,258**
Earnings per share (expressed in RMB per share)		
From continuing and discontinued operations		
— Basic	4.16	2.25
— Diluted	4.12	2.24
From continuing operations		
— Basic	4.20	2.49
— Diluted	4.17	2.48

Condensed Consolidated Statement of Financial Position
As at September 30, 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	As at September 30, 2025	As at December 31, 2024
Non-current Assets		
Property, plant and equipment	25,662,466	25,267,837
Right-of-use assets	1,837,014	1,874,838
Goodwill	865,960	972,352
Other intangible assets	420,103	600,995
Interests in associates	1,939,168	2,322,170
Interests in joint ventures	3,911	3,378
Deferred tax assets	512,940	473,067
Financial assets at fair value through profit or loss ("**FVTPL**")	8,350,830	8,943,404
Other non-current assets	115,733	114,662
Biological assets	1,085,705	1,062,969
Total Non-current Assets	**40,793,830**	**41,635,672**
Current Assets		
Inventories	6,011,008	3,532,083
Contract costs	929,035	912,184
Biological assets	903,702	955,480
Amounts due from related parties	115,531	89,253
Trade and other receivables	10,731,643	9,643,717
Contract assets	819,019	988,836
Income tax recoverable	42,756	87,171
Financial assets at FVTPL	3,560,952	1,233,984
Derivative financial instruments	1,826	—
Other current assets	742,342	734,078
Pledged bank deposits	57,518	22,120
Term deposits with initial term of over three months	3,921,390	4,865,627
Bank balances and cash	25,459,856	13,434,287
	53,296,578	36,498,820
Assets classified as held for sale	515,727	2,191,332

	As at September 30, 2025	As at December 31, 2024
Total Current Assets	**53,812,305**	**38,690,152**
Total Assets	**94,606,135**	**80,325,824**
Current Liabilities		
Trade and other payables	7,746,529	7,025,501
Amounts due to related parties	7,864	15,345
Derivative financial instruments	2,856	202,036
Contract liabilities	2,565,674	2,251,025
Bank borrowings	5,282,147	1,278,629
Lease liabilities	179,867	224,158
Income tax payables	2,249,875	870,796
Convertible bonds	1,294,459	3,493,084
	19,329,271	15,360,574
Liabilities directly associated with assets classified as held for sale	108,984	865,541
Total Current Liabilities	**19,438,255**	**16,226,115**
Non-current Liabilities		
Bank borrowings	1,799,100	2,959,509
Deferred tax liabilities	433,704	522,414
Deferred income	929,904	985,612
Lease liabilities	532,675	546,561
Total Non-current Liabilities	**3,695,383**	**5,014,096**
Total Liabilities	**23,133,638**	**21,240,211**
Capital and Reserves		
Share capital	2,965,693	2,887,993
Reserves	67,982,427	55,744,722
Equity attributable to owners of the Company	70,948,120	58,632,715
Non-controlling interests	524,377	452,898
Total Equity	**71,472,497**	**59,085,613**

Condensed Consolidated Statement of Cash Flows
January to September 2025

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First three quarters of 2025 (January – September)	**First three quarters of 2024 (January – September)**
Net cash from operating activities	**10,872,887**	**8,052,215**
Investing activities		
Interests received	518,188	381,651
Proceeds from disposal of financial assets at FVTPL	6,859,776	4,272,265
Proceeds from partial disposal of associates and a joint venture	3,503,516	6,301
Purchases of financial assets at FVTPL	(8,635,082)	(4,238,584)
Withdrawal of certificates of deposits	—	700,000
Purchases of term deposits with initial term of over three months	—	(1,459,720)
Withdrawal of term deposits with initial term of over three months	835,918	362,825
Proceeds from disposal of other intangible assets	—	244
Proceeds from disposal of property, plant and equipment	9,761	9,490
Capital injection to an associate	(5,601)	(12,220)
Purchases of property, plant and equipment	(3,556,029)	(2,490,515)
Purchases of other intangible assets	(540)	(1,139)
Payments for right-of-use assets	(9,748)	—
Withdrawal of rental deposits	1,449	719
(Placement) withdrawal of pledged bank deposits	(5,869)	7
Dividends received from financial assets at FVTPL	45,411	74,368
Dividends received from associates	143,186	—
Payments on derivative financial instruments	(36,444)	(511,220)
R&D grants and others received related to assets	41,046	38,907
Payments on discontinued operations	(106,458)	—
Net cash inflow on disposal of subsidiaries	1,343,881	—

	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September)
Net cash from (used in) investing activities	**946,361**	**(2,866,621)**
Financing activities		
Payments of dividends	(4,898,653)	(2,882,051)
New bank borrowings raised	11,575,750	8,265,727
Repayments of bank borrowings	(8,718,797)	(6,957,912)
Repayments of lease liabilities	(175,463)	(212,625)
Proceeds from the placing of new H Shares	6,995,824	—
Net proceeds from exercise of stock option	—	16,428
Interests paid	(68,148)	(167,690)
Acquisition of partial interest of subsidiaries from non-controlling shareholders	(61)	(58,570)
Payments on repurchase of A Shares and H Shares	(4,289,244)	(3,908,910)
Net cash from (used in) financing activities	**421,208**	**(5,905,603)**
Net increase (decrease) in cash and cash equivalents	**12,240,456**	**(720,009)**
Cash and cash equivalents at the beginning of the period	**13,444,711**	**10,001,039**
Effects of exchange rate changes	(209,210)	(9,427)
Cash and cash equivalents at the end of the period	**25,475,957**	**9,271,603**

5. Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

Unit: RMB million Type of audit: Unaudited

	Third quarter of 2025 (July – September)	Third quarter of 2024 (July – September)	First three quarters of 2025 (January – September)	First three quarters of 2024 (January – September)
Net profit attributable to the owners of the Company	**3,514.6**	**2,293.1**	**11,801.9**	**6,532.9**
Add:				
Share-based compensation expenses	249.9	79.4	426.3	244.4
Issuance expenses of convertible bonds	8.7	—	28.4	—
Foreign exchange related losses	100.0	629.8	548.0	658.7
Amortization of acquired intangible assets from merger and acquisition	6.7	13.3	20.5	40.3
Gains or losses from divestiture, restructuring and resource integration initiatives	88.4	—	228.3	—
Non-IFRS net profit attributable to the owners of the Company	**3,968.5**	**3,015.6**	**13,053.5**	**7,476.3**
Add:				
Realized and unrealized losses (gains) from venture capital investments	254.4	(41.9)	(2,515.7)	(134.6)
Realized and unrealized share of (gains) losses from joint ventures	(0.6)	(0.2)	(0.6)	4.0
Adjusted non-IFRS net profit attributable to the owners of the Company	**4,222.3**	**2,973.5**	**10,537.1**	**7,345.7**

Note: Any discrepancies between the total shown and the sum of the amounts listed in the above table are due to rounding.